|
Delayed
Athens S.E.
04:44:13 2026-08-18 EDT
|
5-day change | 1st Jan Change | ||
| 4.210 EUR | +3.19% |
|
+9.35% | +16.62% |
| 04-18 | Evrofarma SA Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| 04-17 | Evrofarma FY 2025 net profit at EUR 3.5 million, up 55% YoY | RE |
Company Valuation: Evrofarma SA
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 13.04 | 12.44 | 9.735 | 16.41 | 24.75 | 49.36 |
| Change | - | -4.61% | -21.76% | 68.54% | 50.83% | 99.45% |
| Enterprise Value (EV) 1 | 31.15 | 33.5 | 29.68 | 35.28 | 38.38 | 59.86 |
| Change | - | 7.54% | -11.42% | 18.87% | 8.78% | 55.97% |
| P/E | 12.1x | -35x | 6.86x | 7.45x | 10.9x | 14x |
| PBR | 1.01x | 0.99x | 0.69x | 1.01x | 1.39x | 2.39x |
| PEG | - | 0x | -0x | 0.1x | 3.05x | 0.3x |
| Capitalization / Revenue | 0.38x | 0.34x | 0.21x | 0.34x | 0.54x | 1x |
| EV / Revenue | 0.92x | 0.91x | 0.65x | 0.72x | 0.84x | 1.21x |
| EV / EBITDA | 11x | 20.5x | 7.04x | 6.64x | 6.99x | 9.15x |
| EV / EBIT | 20.8x | 145x | 10.9x | 9.65x | 10.3x | 13x |
| EV / FCF | 409x | -13.8x | 42.8x | 51.7x | 9.61x | -101x |
| FCF Yield | 0.24% | -7.27% | 2.34% | 1.93% | 10.4% | -0.99% |
| Dividend per Share 2 | - | - | - | 0.05 | 0.05 | 0.06 |
| Rate of return | - | - | - | 4.17% | 2.76% | 1.66% |
| EPS 2 | 0.079 | -0.026 | 0.1038 | 0.161 | 0.1667 | 0.2579 |
| Distribution rate | - | - | - | 31.1% | 30% | 23.3% |
| Net sales 1 | 33.91 | 36.7 | 45.38 | 48.76 | 45.72 | 49.44 |
| EBITDA 1 | 2.839 | 1.634 | 4.218 | 5.312 | 5.494 | 6.544 |
| EBIT 1 | 1.497 | 0.231 | 2.725 | 3.655 | 3.727 | 4.595 |
| Net income 1 | 1.08 | -0.355 | 1.419 | 2.202 | 2.28 | 3.526 |
| Net Debt 1 | 18.11 | 21.06 | 19.94 | 18.87 | 13.63 | 10.5 |
| Reference price 2 | 0.954 | 0.910 | 0.712 | 1.200 | 1.810 | 3.610 |
| Nbr of stocks (in thousands) | 13,673 | 13,673 | 13,673 | 13,673 | 13,673 | 13,673 |
| Announcement Date | 4/29/21 | 4/29/22 | 4/18/23 | 3/29/24 | 4/18/26 | 4/18/26 |
1EUR in Million2EUR
Estimates
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 64.61M | |
| 12.91x | 1.52x | 10.43x | 5.99% | 23.67B | |
| 20.14x | 1.63x | 12.45x | 1.86% | 6.31B | |
| 38.34x | 3.43x | 22.21x | 2.55% | 5.95B | |
| 19.21x | 1.11x | 10.57x | 2.12% | 5.69B | |
| 9.77x | 0.96x | 4.41x | 3.13% | 4.9B | |
| 13.07x | 1.62x | 8.11x | 7.19% | 4.96B | |
| 10.71x | 0.87x | 3.88x | 7.18% | 3.66B | |
| Average | 17.74x | 1.59x | 10.29x | 4.29% | 6.9B | |
| Weighted average by Cap. | 16.72x | 1.61x | 10.77x | 4.68% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- EVROF Stock
- Valuation Evrofarma SA
Select your edition
All financial news and data tailored to specific country editions
